CollPlant Biotechnologies (CLGN) Receives Buy Recommendation with 436.16% Upside Potential from D. Boral Capital

sábado, 29 de noviembre de 2025, 1:09 am ET1 min de lectura
CLGN--

D. Boral Capital maintains a Buy recommendation for CollPlant Biotechnologies (CLGN) with an average one-year price target of $11.73/share, a 436.16% increase from its latest reported closing price. The projected annual revenue is 5,277MM, a 213,112.12% increase. There are 17 funds or institutions reporting positions in CLGN, with an average portfolio weight of 0.05%.

CollPlant Biotechnologies (CLGN) Receives Buy Recommendation with 436.16% Upside Potential from D. Boral Capital

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios